311 related articles for article (PubMed ID: 20051277)
21. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate.
Matoba N; Geyer BC; Kilbourne J; Alfsen A; Bomsel M; Mor TS
Vaccine; 2006 Jun; 24(23):5047-55. PubMed ID: 16621185
[TBL] [Abstract][Full Text] [Related]
22. Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors.
Ko SY; Cheng C; Kong WP; Wang L; Kanekiyo M; Einfeld D; King CR; Gall JG; Nabel GJ
J Virol; 2009 Jan; 83(2):748-56. PubMed ID: 18987146
[TBL] [Abstract][Full Text] [Related]
23. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.
Tan GS; McKenna PM; Koser ML; McLinden R; Kim JH; McGettigan JP; Schnell MJ
Virology; 2005 Jan; 331(1):82-93. PubMed ID: 15582655
[TBL] [Abstract][Full Text] [Related]
24. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
[TBL] [Abstract][Full Text] [Related]
25. Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens.
Center RJ; Wheatley AK; Campbell SM; Gaeguta AJ; Peut V; Alcantara S; Siebentritt C; Kent SJ; Purcell DF
Vaccine; 2009 Nov; 27(47):6605-12. PubMed ID: 19712773
[TBL] [Abstract][Full Text] [Related]
26. DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice.
Rasmussen RA; Ong H; Kittel C; Ruprecht CR; Ferrantelli F; Hu SL; Polacino P; McKenna J; Moon J; Travis B; Ruprecht RM
Vaccine; 2006 Mar; 24(13):2324-32. PubMed ID: 16406147
[TBL] [Abstract][Full Text] [Related]
27. Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV.
Xin KQ; Sekimoto Y; Takahashi T; Mizuguchi H; Ichino M; Yoshida A; Okuda K
Vaccine; 2007 May; 25(19):3809-15. PubMed ID: 17386962
[TBL] [Abstract][Full Text] [Related]
28. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.
Asmuth DM; Brown EL; DiNubile MJ; Sun X; del Rio C; Harro C; Keefer MC; Kublin JG; Dubey SA; Kierstead LS; Casimiro DR; Shiver JW; Robertson MN; Quirk EK; Mehrotra DV
J Infect Dis; 2010 Jan; 201(1):132-41. PubMed ID: 19929694
[TBL] [Abstract][Full Text] [Related]
29. [Anti-adenovirus neutralizing antibodies and Gag-specific cellular immune responses in Macaca fascicularis immunized with Ad5-HIVgag].
Li Y; Yang L; Yang L; Chen DY; Feng X; Yu SQ; Li ZL; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Dec; 25(6):413-5. PubMed ID: 22734222
[TBL] [Abstract][Full Text] [Related]
30. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
31. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
32. Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.
Bett AJ; Dubey SA; Mehrotra DV; Guan L; Long R; Anderson K; Collins K; Gaunt C; Fernandez R; Cole S; Meschino S; Tang A; Sun X; Gurunathan S; Tartaglia J; Robertson MN; Shiver JW; Casimiro DR
Vaccine; 2010 Nov; 28(50):7881-9. PubMed ID: 20937317
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1.
Ranasinghe C; Medveczky JC; Woltring D; Gao K; Thomson S; Coupar BE; Boyle DB; Ramsay AJ; Ramshaw IA
Vaccine; 2006 Jul; 24(31-32):5881-95. PubMed ID: 16759767
[TBL] [Abstract][Full Text] [Related]
34. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
35. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
Jiang W; Ren L; Jin N
J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
[TBL] [Abstract][Full Text] [Related]
36. Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen.
Jain S; Patrick AJ; Rosenthal KL
Vaccine; 2010 Oct; 28(43):7070-80. PubMed ID: 20723627
[TBL] [Abstract][Full Text] [Related]
37. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.
Paris RM; Kim JH; Robb ML; Michael NL
Expert Rev Vaccines; 2010 Sep; 9(9):1055-69. PubMed ID: 20822348
[TBL] [Abstract][Full Text] [Related]
38. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.
Casimiro DR; Chen L; Fu TM; Evans RK; Caulfield MJ; Davies ME; Tang A; Chen M; Huang L; Harris V; Freed DC; Wilson KA; Dubey S; Zhu DM; Nawrocki D; Mach H; Troutman R; Isopi L; Williams D; Hurni W; Xu Z; Smith JG; Wang S; Liu X; Guan L; Long R; Trigona W; Heidecker GJ; Perry HC; Persaud N; Toner TJ; Su Q; Liang X; Youil R; Chastain M; Bett AJ; Volkin DB; Emini EA; Shiver JW
J Virol; 2003 Jun; 77(11):6305-13. PubMed ID: 12743287
[TBL] [Abstract][Full Text] [Related]
39. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
[TBL] [Abstract][Full Text] [Related]
40. Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.
Hrycak CP; Windmann S; Bayer W
J Virol; 2019 Nov; 93(21):. PubMed ID: 31375593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]